CTX.TO (Mkap C$ 7.7 M) 1x FDA approved /2x Phase 3 und weitere Produkte am Markt (Seite 8)
eröffnet am 10.01.18 20:30:45 von
neuester Beitrag 17.03.24 19:06:07 von
neuester Beitrag 17.03.24 19:06:07 von
Beiträge: 157
ID: 1.271.450
ID: 1.271.450
Aufrufe heute: 1
Gesamt: 23.361
Gesamt: 23.361
Aktive User: 0
ISIN: CA2258471028 · WKN: A2AD5R · Symbol: CTX
0,4400
CAD
0,00 %
0,0000 CAD
Letzter Kurs 24.04.24 Toronto
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 6,0000 | +25,00 | |
| 0,6674 | +21,35 | |
| 0,6950 | +19,11 | |
| 9,5000 | +18,75 | |
| 0,6400 | +18,52 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 9,7200 | -19,60 | |
| 0,9250 | -23,55 | |
| 4,0000 | -27,27 | |
| 2,7280 | -29,14 | |
| 14,510 | -32,32 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 61.207.175 von Palawanobi am 08.08.19 14:06:38
http://crescitatherapeutics.mediaroom.com/2019-10-28-Sundial…
Die nächsten Zahlen stehen auch bald an (1-2 Wochen), dann denke ich werden wir spätestens eine Stufe höher stehen!
Neue Partnerschaft
So langsam müsste hier eigentlich mal mehr Phantasie reinkommen:http://crescitatherapeutics.mediaroom.com/2019-10-28-Sundial…
Die nächsten Zahlen stehen auch bald an (1-2 Wochen), dann denke ich werden wir spätestens eine Stufe höher stehen!
Crescita Reports Profitable 2019 Second Quarter Results
Q1-F2019 Year-over-Year Financial Highlights
- Revenue of $4.2 million, an increase of $0.6 million or 16.4% vs Q1-2018;
- Received a $1.3 million (US$1.0 million) sales milestone from Taro on the achievement of the 3rd cumulative sales target (included in revenue above);
- Operating expenses of $3.8 million, down $0.2 million or 4.0% versus Q1-2018;
- Adjusted EBITDA1 of $1.0 million, an improvement of $0.9 million versus Q1-2018;
- Generated $2.3 million in cash during the quarter, resulting in an ending cash and cash equivalents balance of $10.9 million as at March 31, 2019, compared to $8.6 million at the end of Q4-2018;
- Launched Dermazulene™ in China, a product specifically designed and created for the Chinese market, which is distributed through the leading cross-border e-commerce platform in China.
- Entered into an agreement with Tetra Natural Health ("Tetra") on February 4, 2019, to develop an enhanced version of Tetra's dermatology portfolio using Crescita's patented transdermal delivery technologies: MMPE™ and DuraPeel™.
"I am pleased with the positive momentum our team has generated in the first quarter of fiscal 2019, as demonstrated by our revenue and Adjusted EBITDA growth, as well as our strong cash position," said Serge Verreault President and Chief Executive Officer of Crescita. "Our results underscore the strength of our four-pillar growth strategy. We will remain focused on the fundamentals of our business to drive sustainable profitable growth in 2019."
https://www.newswire.ca/news-releases/crescita-therapeutics-…
Q1-F2019 Year-over-Year Financial Highlights
- Revenue of $4.2 million, an increase of $0.6 million or 16.4% vs Q1-2018;
- Received a $1.3 million (US$1.0 million) sales milestone from Taro on the achievement of the 3rd cumulative sales target (included in revenue above);
- Operating expenses of $3.8 million, down $0.2 million or 4.0% versus Q1-2018;
- Adjusted EBITDA1 of $1.0 million, an improvement of $0.9 million versus Q1-2018;
- Generated $2.3 million in cash during the quarter, resulting in an ending cash and cash equivalents balance of $10.9 million as at March 31, 2019, compared to $8.6 million at the end of Q4-2018;
- Launched Dermazulene™ in China, a product specifically designed and created for the Chinese market, which is distributed through the leading cross-border e-commerce platform in China.
- Entered into an agreement with Tetra Natural Health ("Tetra") on February 4, 2019, to develop an enhanced version of Tetra's dermatology portfolio using Crescita's patented transdermal delivery technologies: MMPE™ and DuraPeel™.
"I am pleased with the positive momentum our team has generated in the first quarter of fiscal 2019, as demonstrated by our revenue and Adjusted EBITDA growth, as well as our strong cash position," said Serge Verreault President and Chief Executive Officer of Crescita. "Our results underscore the strength of our four-pillar growth strategy. We will remain focused on the fundamentals of our business to drive sustainable profitable growth in 2019."
https://www.newswire.ca/news-releases/crescita-therapeutics-…
Laeuft 
Antwort auf Beitrag Nr.: 60.954.598 von Palawanobi am 04.07.19 14:08:27Das ist mal ne Ansage, +17% mit starken Volumen ohne News, ich denke da kommt in den naechsten Tagen etwas sehr positives! :-)
Crescita Therapeutics Inc. Receives 2nd Instalment of Up-Front Payment of €1.25 Million
Following First Commercial Sale of Pliaglis by Cantabria in Italy
https://www.newswire.ca/news-releases/crescita-therapeutics-…
Following First Commercial Sale of Pliaglis by Cantabria in Italy
https://www.newswire.ca/news-releases/crescita-therapeutics-…
Trading Spotlight
Präsentation von der LD Micro Invitational
https://seekingalpha.com/article/4269071-crescita-therapeuti…
https://seekingalpha.com/article/4269071-crescita-therapeuti…
Crescita to Present at the 9th Annual LD Micro Invitational in Los Angeles, California
LAVAL, QC, May 30, 2019 /CNW/ - Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (Crescita or the Company), a Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, announced today that its Executive Chairman, Dan Chicoine will be presenting at the 9th annual LD Micro Invitational on Tuesday, June 4th at 3:00 p.m. pacific time. Mr. Chicoine accompanied by Ms. Linda Kisa, Crescita's director of investor relations, will also be meeting with investors one-on-one.
"We are very excited to be presenting at this prestigious conference and we look forward to introducing Crescita to a new list of potential U.S. investors" stated Dan Chicoine, executive chairman.
The LD Micro Invitational will take place June 4th and 5th in Los Angeles, at the Luxe Sunset Bel Air Hotel, will feature 230 companies, and will be attended by over 1,000 individuals.
Please visit https://www.ldmicro.com/profile/CTX.TO to view Crescita Therapeutics' profile.
https://www.newswire.ca/news-releases/crescita-to-present-at…
LAVAL, QC, May 30, 2019 /CNW/ - Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (Crescita or the Company), a Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, announced today that its Executive Chairman, Dan Chicoine will be presenting at the 9th annual LD Micro Invitational on Tuesday, June 4th at 3:00 p.m. pacific time. Mr. Chicoine accompanied by Ms. Linda Kisa, Crescita's director of investor relations, will also be meeting with investors one-on-one.
"We are very excited to be presenting at this prestigious conference and we look forward to introducing Crescita to a new list of potential U.S. investors" stated Dan Chicoine, executive chairman.
The LD Micro Invitational will take place June 4th and 5th in Los Angeles, at the Luxe Sunset Bel Air Hotel, will feature 230 companies, and will be attended by over 1,000 individuals.
Please visit https://www.ldmicro.com/profile/CTX.TO to view Crescita Therapeutics' profile.
https://www.newswire.ca/news-releases/crescita-to-present-at…
Crescita Therapeutics Engages Bristol Capital
to Provide Investor Relations and Communications Services
LAVAL, QC, May 29, 2019 /CNW/ - Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (Crescita or the Company), a Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, announced today that it has entered into a consulting agreement with Bristol Capital LTD. ("Bristol"), a leading investor relations firm servicing Canadian and US microcap and small cap companies across international markets, to provide investor relations and communication services.
Bristol will provide investor relations services to Crescita, including introductions to Bristol's direct network of investment professionals, coordination of public events and proactive investor relations campaigns to increase Crescita's exposure in the investment community.
Serge Verreault, Crescita's President and CEO stated, "We are pleased to engage Bristol Capital at this very opportune time of growth. We are focused on enhancing our investor outreach to tell the Crescita story and look forward to working with the Bristol team in establishing excellence in our investor relations initiatives. We chose Bristol Capital because of their great reputation and extensive network with retail and institutional investors and are confident they will quickly engage and grow our stakeholder base."
The Company and Bristol act at arm's length, and Bristol has no present interest, directly or indirectly, in the Company or its securities. The fees paid by the Company to Bristol are for its services only.
https://www.newswire.ca/news-releases/crescita-therapeutics-…
to Provide Investor Relations and Communications Services
LAVAL, QC, May 29, 2019 /CNW/ - Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (Crescita or the Company), a Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, announced today that it has entered into a consulting agreement with Bristol Capital LTD. ("Bristol"), a leading investor relations firm servicing Canadian and US microcap and small cap companies across international markets, to provide investor relations and communication services.
Bristol will provide investor relations services to Crescita, including introductions to Bristol's direct network of investment professionals, coordination of public events and proactive investor relations campaigns to increase Crescita's exposure in the investment community.
Serge Verreault, Crescita's President and CEO stated, "We are pleased to engage Bristol Capital at this very opportune time of growth. We are focused on enhancing our investor outreach to tell the Crescita story and look forward to working with the Bristol team in establishing excellence in our investor relations initiatives. We chose Bristol Capital because of their great reputation and extensive network with retail and institutional investors and are confident they will quickly engage and grow our stakeholder base."
The Company and Bristol act at arm's length, and Bristol has no present interest, directly or indirectly, in the Company or its securities. The fees paid by the Company to Bristol are for its services only.
https://www.newswire.ca/news-releases/crescita-therapeutics-…
Crescita Therapeutics Reports 2019 First Quarter Results
Q1-F2019 Year-over-Year Financial Highlights
- Revenue of $4.2 million, an increase of $0.6 million or 16.4% vs Q1-2018;
- Received a $1.3 million (US$1.0 million) sales milestone from Taro on the achievement of the 3rd
cumulative sales target (included in revenue above);
- Operating expenses of $3.8 million, down $0.2 million or 4.0% versus Q1-2018;
- Adjusted EBITDA1 of $1.0 million, an improvement of $0.9 million versus Q1-2018;
- Generated $2.3 million in cash during the quarter, resulting in an ending cash and cash equivalents
balance of $10.9 million as at March 31, 2019, compared to $8.6 million at the end of Q4-2018;
- Launched Dermazulene™ in China, a product specifically designed and created for the Chinese
market, which is distributed through the leading cross-border e-commerce platform in China.
- Entered into an agreement with Tetra Natural Health ("Tetra") on February 4, 2019, to develop an
enhanced version of Tetra's dermatology portfolio using Crescita's patented transdermal delivery
technologies: MMPE™ and DuraPeel™.
https://www.prnewswire.com/news-releases/crescita-therapeuti…
Q1-F2019 Year-over-Year Financial Highlights
- Revenue of $4.2 million, an increase of $0.6 million or 16.4% vs Q1-2018;
- Received a $1.3 million (US$1.0 million) sales milestone from Taro on the achievement of the 3rd
cumulative sales target (included in revenue above);
- Operating expenses of $3.8 million, down $0.2 million or 4.0% versus Q1-2018;
- Adjusted EBITDA1 of $1.0 million, an improvement of $0.9 million versus Q1-2018;
- Generated $2.3 million in cash during the quarter, resulting in an ending cash and cash equivalents
balance of $10.9 million as at March 31, 2019, compared to $8.6 million at the end of Q4-2018;
- Launched Dermazulene™ in China, a product specifically designed and created for the Chinese
market, which is distributed through the leading cross-border e-commerce platform in China.
- Entered into an agreement with Tetra Natural Health ("Tetra") on February 4, 2019, to develop an
enhanced version of Tetra's dermatology portfolio using Crescita's patented transdermal delivery
technologies: MMPE™ and DuraPeel™.
https://www.prnewswire.com/news-releases/crescita-therapeuti…
Aus dem Stockhouse-Forum:
http://www.canadianvaluestocks.com/crescita-therapeutics/
http://www.canadianvaluestocks.com/crescita-therapeutics/
Durchsuchen
